fda deadline tirzepatide says shortage is over after taking a second look Important Notice: Tirzepatide Compounding Update

Average weight loss is around 5%, with about 55% of patients losing 5% or more of their starting weight.[1] Contrave can be a strong fit for patients whose weight is closely tied to emotional eating or food cravings and for patients who also have depression and could benefit from the antidepressant effect

And it costs a fraction of the price of branded versions

In cases of intolerable side effects despite management strategies, dose reduction or discontinuation may be necessary

No, the push means sort of grant funding investment

Patients are encouraged to report any suspected adverse reactions to Mounjaro via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)